Recombinante mas costo efectiva que la viva...HZV

New Zoster Vaccine More Cost-Effective Than Old One

By Amy Orciari Herman

Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD

The new recombinant zoster vaccine (RZV; Shingrix) is more cost-effective than the live attenuated vaccine (ZVL; Zostavax), according to a CDC-funded study in the Annals of Internal Medicine.

Using a simulation model, researchers examined the following among immunocompetent adults aged 50 and older:

• Cost-effectiveness of RZV versus ZVL or no vaccination
• Cost-effectiveness of RZV among people who've already received ZVL
• Cost-effectiveness of preferential immunization with RZV over ZVL

RZV was consistently more cost-effective than ZVL, even in a scenario in which half the adults received just the first of the two RZV doses.

The findings align with CDC recommendations, which advise that RZV be preferred over ZVL and that RZV be given to those who've previously received ZVL.

Asked to comment, infectious diseases specialist Dr. Paul Sax said: "The results of this analysis are not surprising given the greater efficacy of the RZV over the live virus vaccine. Clinicians have already embraced this new recommendation, with the largest barrier to implementation the ongoing national shortage of the vaccine."

Annals of Internal Medicine article (Free abstract)

Annals of Internal Medicine editorial (Subscription required)

Background: NEJM Journal Watch General Medicine coverage of comparison of zoster vaccines (Your NEJM Journal Watch subscription required)

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.